American Eastern Securities Group

American Eastern Biotech, formerly known as American Eastern Securities, was a pharmaceutical company primarily focused on the Chinese market. The company specialized in the development, manufacture, and distribution of traditional Chinese medicine (TCM) and Western pharmaceutical products, including cardiovascular treatments and antibiotics. Operating through its subsidiaries such as Anhui Kelong Pharmaceutical, it maintained a portfolio of over 100 products. Although it was publicly traded on the OTC market under the symbol AEBT, the company has since become inactive and is no longer operational. The firm's history is notable for its transition from a financial services entity to a life sciences company via reverse merger.